Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.

Urology. 2013 Mar;81(3):611-6. doi: 10.1016/j.urology.2012.12.025.

PMID:
23452809
2.

Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Taneja SS.

J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.105. Epub 2013 Jun 7. No abstract available.

PMID:
23931194
3.

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.

Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.

J Clin Oncol. 2006 Dec 1;24(34):5408-13.

4.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

5.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
6.

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Amato R, Stepankiw M, Gonzales P.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1629-34. doi: 10.1007/s00280-013-2163-4. Epub 2013 Apr 21.

PMID:
23604530
7.

A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.

Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ.

Eur J Cancer. 2015 Aug;51(12):1555-69. doi: 10.1016/j.ejca.2015.04.028. Epub 2015 Jun 2.

PMID:
26048455
8.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22.

9.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
10.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.

Eur Urol. 1996;29 Suppl 2:105-9.

PMID:
8717471
11.

Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.

Int J Clin Oncol. 2011 Dec;16(6):630-6. doi: 10.1007/s10147-011-0232-4. Epub 2011 Apr 23.

PMID:
21512893
13.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S.

Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24.

PMID:
22119204
14.

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.

Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL.

Clin Genitourin Cancer. 2015 Feb;13(1):e1-6. doi: 10.1016/j.clgc.2014.06.016. Epub 2014 Jun 27.

PMID:
25103271
15.

Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.

Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):529-33. doi: 10.1016/j.ijrobp.2013.02.004. Epub 2013 Mar 21.

PMID:
23523323
16.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
17.

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.

Urology. 1996 Jan;47(1A Suppl):54-60; discussion 80-4.

PMID:
8560679
18.

Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.

Lee JL, Eun Kim J, Ahn JH, Lee DH, Lee J, Kim CS, Hyuk Hong J, Hong B, Song C, Ahn H.

Am J Clin Oncol. 2011 Apr;34(2):140-4. doi: 10.1097/COC.0b013e3181d2ed7d.

PMID:
20686407
19.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

20.

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T.

Semin Oncol. 2001 Aug;28(4 Suppl 15):22-31.

PMID:
11685725
Items per page

Supplemental Content

Write to the Help Desk